Top challenges likely to slow adoption of biosimilars March 30, 2017 By Bryant Furlow Biosimilars will reshape clinical care and managed care pharmacy but ambiguities in the regulatory landscape and knowledge gaps among clinicians seem likely slow adoption. Top considerations when determining whether to approve expensive drugs March 29, 2017 By Bryant Furlow Weighing the ethics of approving expensive cancer drugs for patients facing terminal disease is a multifaceted endeavor. Here are some recommendations. Expedited FDA approval plays dominant role in drug approvals March 29, 2017 By Bryant Furlow Last year was a banner year for generic drug approvals by the FDA. Find out what’s in store for 2017. Payers strategize to manage opioid use March 28, 2017 By Tracey Walker How managed care organizations manage opioid utilization and some of the limitations to those management strategies was a hot topic at the AMCP Annual Meeting. Creating a ‘robust’ specialty pharmacy network March 28, 2017 By Tracey Walker The correct approach to take when creating a specialty pharmacy network is a key issue for healthcare executives. FDA approvals for specialty drugs to pick up in 2017 March 28, 2017 By Bryant Furlow Numerous specialty medications, generics, and biosimilars, are expected to be approved this year for cancer, inflammatory and autoimmune diseases, and other indications. State medical marijuana laws continue to expand March 28, 2017 By Bryant Furlow Medical marijuana’s therapeutic evidence base remains nascent and controversial but the regulatory landscape is evolving rapidly. Insulin treatment persistence varies among payers March 24, 2017 By Tracey Walker A study from Walgreens provides a benchmark of basal insulin treatment persistence across different payers in the United States. Five things to know about Trump’s FDA lead pick Gottlieb March 23, 2017 By Karen Appold On March 10, the White House announced that President Donald Trump selected Scott Gottlieb, MD, who has worked for FDA in the past, as his choice to head the FDA. Here are five things managed healthcare executives should know about the pick.